Pharma industry raises concerns over new Schedule M's impact on cosmetic manufacturing

The pharmaceutical industry, represented by the Federation of Pharma Enterprises (FoPE), has expressed concerns over the government's new Schedule M, which prohibits the manufacture of any product other than drugs in units licensed for drug production. FoPE argues that setting up a separate plant for cosmetic manufacturing is financially unviable for medium and small-scale enterprises. They are requesting permission to manufacture cosmetics in the area designated for topical products like creams and lotions.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/LVCr1eR
via IFTTT